Majority of consumers hope to use voice assistants for healthcare

Just 7.5% of consumers in the United States have used voice assistant technology—Amazon’s Alexa, for example—for healthcare. According to a new report, however, 52% want to use it for that purpose in the future.

The report, conducted by Voicebot.ai and Orbita, included survey responses from more than 1,000 consumers. Data was collected in September 2019. The full report is available to download on the Voicebot.ai website.

“This report is the first comprehensive analysis that considers how consumers are using voice assistants today for healthcare-related needs, explores features they'd like to see in the future, and highlights how provider and technology organizations have responded to the opportunity thus far,” Orbita President Nathan Treloar said in a prepared statement.

“We are pleased to collaborate with Orbita to publish the first comprehensive report analyzing the intersection of voice assistants and healthcare,” Bret Kinsella, founder and CEO of Voicebot.ai, said in the same statement. “Consumers are enthusiastic about the potential of these new technologies and we hope the data helps healthcare organizations better understand the market and make decisions about how they can leverage voice assistants to enhance patient engagement.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.